591 related articles for article (PubMed ID: 29882797)
1. Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy.
Singh AK; Bishayee A; Pandey AK
Nutrients; 2018 Jun; 10(6):. PubMed ID: 29882797
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
3. Anticancer clinical efficiency and stochastic mechanisms of belinostat.
El Omari N; Bakrim S; Khalid A; Albratty M; Abdalla AN; Lee LH; Goh KW; Ming LC; Bouyahya A
Biomed Pharmacother; 2023 Sep; 165():115212. PubMed ID: 37541175
[TBL] [Abstract][Full Text] [Related]
4. Progress in discovery and development of natural inhibitors of histone deacetylases (HDACs) as anti-cancer agents.
Wahi A; Jain P; Sinhari A; Jadhav HR
Naunyn Schmiedebergs Arch Pharmacol; 2024 Feb; 397(2):675-702. PubMed ID: 37615708
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitors selectively suppress expression of HDAC7.
Dokmanovic M; Perez G; Xu W; Ngo L; Clarke C; Parmigiani RB; Marks PA
Mol Cancer Ther; 2007 Sep; 6(9):2525-34. PubMed ID: 17876049
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic Targeting of Autophagy via HDAC Inhibition in Tumor Cells: Role of p53.
Mrakovcic M; Bohner L; Hanisch M; Fröhlich LF
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544838
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors in hematological malignancies and solid tumors.
Chun P
Arch Pharm Res; 2015 Jun; 38(6):933-49. PubMed ID: 25653088
[TBL] [Abstract][Full Text] [Related]
8. HDAC inhibitor-based therapies: can we interpret the code?
New M; Olzscha H; La Thangue NB
Mol Oncol; 2012 Dec; 6(6):637-56. PubMed ID: 23141799
[TBL] [Abstract][Full Text] [Related]
9. Histone Deacetylase Inhibitors as Anticancer Drugs.
Eckschlager T; Plch J; Stiborova M; Hrabeta J
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28671573
[TBL] [Abstract][Full Text] [Related]
10. The Safety, Efficacy and Therapeutic Potential of Histone Deacetylase Inhibitors with Special Reference to Panobinostat in Gastrointestinal Tumors: A Review of Preclinical and Clinical Studies.
Singh A; Patel P; Jageshwar ; Patel VK; Jain DK; Kamal M; Rajak H
Curr Cancer Drug Targets; 2018; 18(8):720-736. PubMed ID: 28669336
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitors: molecular mechanisms of action.
Xu WS; Parmigiani RB; Marks PA
Oncogene; 2007 Aug; 26(37):5541-52. PubMed ID: 17694093
[TBL] [Abstract][Full Text] [Related]
12. HDAC Inhibitors.
Olzscha H; Bekheet ME; Sheikh S; La Thangue NB
Methods Mol Biol; 2016; 1436():281-303. PubMed ID: 27246222
[TBL] [Abstract][Full Text] [Related]
13. HDACi--going through the mechanisms.
Wanczyk M; Roszczenko K; Marcinkiewicz K; Bojarczuk K; Kowara M; Winiarska M
Front Biosci (Landmark Ed); 2011 Jan; 16(1):340-59. PubMed ID: 21196174
[TBL] [Abstract][Full Text] [Related]
14. Targeting Histone Deacetylases in Malignant Melanoma: A Future Therapeutic Agent or Just Great Expectations?
Garmpis N; Damaskos C; Garmpi A; Dimitroulis D; Spartalis E; Margonis GA; Schizas D; Deskou I; Doula C; Magkouti E; Andreatos N; Antoniou EA; Nonni A; Kontzoglou K; Mantas D
Anticancer Res; 2017 Oct; 37(10):5355-5362. PubMed ID: 28982843
[TBL] [Abstract][Full Text] [Related]
15. Targeting Histone Deacetylases in Diseases: Where Are We?
Benedetti R; Conte M; Altucci L
Antioxid Redox Signal; 2015 Jul; 23(1):99-126. PubMed ID: 24382114
[TBL] [Abstract][Full Text] [Related]
16. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.
LaBonte MJ; Wilson PM; Fazzone W; Groshen S; Lenz HJ; Ladner RD
BMC Med Genomics; 2009 Nov; 2():67. PubMed ID: 19948057
[TBL] [Abstract][Full Text] [Related]
17. Histone Deacetylase Inhibitors (HDACi) Cause the Selective Depletion of Bromodomain Containing Proteins (BCPs).
Mackmull MT; Iskar M; Parca L; Singer S; Bork P; Ori A; Beck M
Mol Cell Proteomics; 2015 May; 14(5):1350-60. PubMed ID: 25755299
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells.
Dejligbjerg M; Grauslund M; Litman T; Collins L; Qian X; Jeffers M; Lichenstein H; Jensen PB; Sehested M
Mol Cancer; 2008 Sep; 7():70. PubMed ID: 18789133
[TBL] [Abstract][Full Text] [Related]
19. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
Hanikoglu A; Hanikoglu F; Ozben T
Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of histone deacetylase as antitumor agents: A critical review.
Manal M; Chandrasekar MJ; Gomathi Priya J; Nanjan MJ
Bioorg Chem; 2016 Aug; 67():18-42. PubMed ID: 27239721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
